CClinicalTrials.gg
CompletedNCT03108820Updated Jun 24, 2024Results posted

Trauma Medical Home for Older Injured Patients

An interventional study of TMH Intervention and Usual Care in Injuries, sponsored by Indiana University. Completed at 4 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-06-24.

Sponsored by Indiana University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This proposal aims to conduct a randomized controlled trial to evaluate the efficacy of a 6-month collaborative care intervention in improving the functional and psychological recovery of 430 injury survivors 50 and older. The trial has the following specific aims: 1) Evaluate the ability of the TMH intervention to improve the physical recovery of older injury survivors; and 2) Evaluate the ability of the TMH intervention to improve the psychological recovery of older injury survivors; and 3) Evaluate the ability of the TMH intervention to reduce healthcare costs of older injury survivors and evaluate the cost of effectiveness of the TMH intervention.

Read the detailed description

Despite the potential for full recovery surprisingly few older injury survivors are able to realize maximal recovery of function and quality of life after injury due to fragmentation of care delivery and lack of focus on psychological symptoms in the early post-injury period. Older injured adults are at particular risk of death and disability after injury. Thus, a fundamental gap in knowledge exists regarding the best way to enhance the recovery of injury survivors. The continued existence of this gap is an important problem because unless it is filled, injury survivors will continue to suffer from potentially reversible impairments of health and well-being. The long-term goal of this line of research is to improve the health and quality of care for injured patients. Indiana University School of Medicine researchers have over 20 years of experience developing innovative and effective collaborative care models that integrate with primary care and specialty physicians to address the complex biopsychosocial needs of patients with chronic disease states, such as dementia and depression. Based on these successes, an interdisciplinary team of clinical investigators at Indiana University revised the collaborative care model to meet the needs of injury survivors who are in an active recovery state. This injury specific collaborative care model is called the Trauma Medical Home (TMH). This proposal aims to conduct a randomized controlled trial to evaluate the efficacy of a 6-month collaborative care intervention in improving the functional and psychological recovery of 430 injury survivors 50 and older. The trial has the following specific aims: 1) Evaluate the ability of the TMH intervention to improve the physical recovery of older injury survivors; and 2) Evaluate the ability of the TMH intervention to improve the psychological recovery of older injury survivors; and 3) Evaluate the ability of the TMH intervention to reduce healthcare costs of older injury survivors and evaluate the cost of effectiveness of the TMH intervention. The research proposed in this application is innovative, in our opinion, because it represents a new and substantive departure from the status quo. Previous collaborative care models focused on chronic care management and they lack rapid adaptability. Because the recovery trajectory of injured patients is dynamic and changes quickly, the innovations in this proposal have to do with providing real-time feedback to a care coordinator that will allow the care coordinator to adjust an injury specific collaborative care protocol to meet the needs of the injured as they move through the dynamic recovery period after injury. This contribution will be significant as broad application of the Trauma Medical Home in trauma centers and trauma systems nationwide could result in better health and improved quality of post-injury care for older injured patients. Improved physical health and fewer psychological symptoms, will likely result in better overall functional ability, the increased ability to return to work and less reliance on family, social, and health care resources.

02

Conditions studied

  • Injuries
03

In context

Lead sponsor

Indiana University is the lead sponsor of 958 studies on the registry; 200 are open to participants now.

Of its 142 completed or terminated interventional studies of FDA-regulated products, 112 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. English-speaking adult age 50 years and older;
  2. admitted to Indiana University Health - Methodist or Eskenazi Health hospitals;
  3. able to provide consent or has a legally authorized representative to provide consent;
  4. access to a telephone;
  5. and an injury severity score (ISS) of 9 or greater.

Exclusion criteria

Exclusion Criteria:

  1. have a self-reported diagnosis of cancer with short life expectancy;
  2. have a history of dementing illnesses and other neurodegenerative disease such as Alzheimer disease, Parkinson disease, or vascular dementia;
  3. have a significant traumatic brain injury (defined as the presence of any intracranial blood on Computed Tomography scan of the head or best Glasgow Coma Scale Score of less than 13 at the time of study enrollment);
  4. have any spinal cord injury with persistent neurologic deficit at the time of study enrollment;
  5. are pregnant women (assessed by a urine pregnancy test);
  6. have a primary residence outside the state of Indiana;
  7. are incarcerated at the time of study enrollment;
  8. have an acute stroke upon admission or develop a stroke as a new event during the course of hospitalization;
  9. unable to complete study questionnaire due to severe hearing loss;
  10. recent history of alcohol or substance abuse;
  11. discharged to a permanent care facility;
  12. admitted with a burn affecting >10% total body surface area.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
430 participants (actual)

Study arms

  • Experimental
    TMH Intervention

    The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.

    Behavioral: TMH Intervention

  • Active comparator
    Usual Care

    Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.

    Other: Usual Care

Interventions

  • BehavioralTMH Intervention

    Home visits and close interaction with injured patient to assure plan for care is being followed.

  • OtherUsual Care

    Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.

06

What researchers measure

Primary outcomes

  1. Change in Self Reported Physical Recovery

    As determined using the Physical Component Score of Short form (SF) SF-36. Score range: 0-100, higher scores indicate a better health state. The change is between baseline and 12 months.

    Time frame: 12 months

  2. Change in Physical Recovery

    As determined using the Short Physical Performance Battery (SPPB). SPPB total score ranges from 0 (worst performance) to 12 points (best performance). The change was determined between baseline and 12 months.

    Time frame: 12 months

  3. Change in Self Reported Psychological Recovery

    As determined using the Mental Component Score of SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 12 months.

    Time frame: 12 months

  4. Healthcare Utilization

    As determined by hospital readmission

    Time frame: 12 months

  5. Change in Self Reported Physical Recovery

    As determined using the Physical Component Score of Short form (SF) SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 6 months.

    Time frame: 6 months

  6. Change in Physical Recovery

    As determined using the Short Physical Performance Battery (SPPB). SPPB total score ranges from 0 (worst performance) to 12 points (best performance). The change was determined between baseline and 6 months.

    Time frame: 6 months

  7. Change in Self Reported Psychological Recovery

    As determined using the Mental Component Score of SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Change in Depression Symptoms

    As determined using the (Patient Health Questionnaire) PHQ-9. The scale is from 1 - 27 with higher scores related to worse depression severity. The change was determined between baseline and 12 months.

    Time frame: 12 months

  2. Change in Anxiety Symptoms

    As determined using the (Generalized Anxiety Disorder) GAD-7. Scores range from 0-21, with higher scores indicating worse symptoms. The change was determined between baseline and 12 months.

    Time frame: 12 months

  3. Cost Effectiveness

    As determined using the cost-effectiveness ratio

    Time frame: 6 and 12 months

  4. Change in Depression Symptoms

    As determined using the (Patient Health Questionnaire) PHQ-9. The scale is from 1 - 27 with higher scores related to worse depression severity. The change was determined between baseline and 6 months.

    Time frame: 6 months

  5. Change in Anxiety Symptoms

    As determined using the (Generalized Anxiety Disorder) GAD-7. Scores range from 0-21, with higher scores indicating worse symptoms. The change was determined between baseline and 6 months.

    Time frame: 6 months

07

Results

Posted Jun 24, 2024
Limitations and caveats
One outcome measure, the SPPB, was only validated in face-to-face assessments but it had to be adapted for telehealth evaluation during the pandemic. Care coordinator visits switched from a combination of in person and remote to fully remote after the pandemic started.

Participant flow

Participant flow — Overall Study
MilestoneTMH InterventionUsual Care
Started216214
6 month assessment158166
Completed148151
Not completed6863
Withdrew: Lost to follow-up3028
Withdrew: Withdrawal by subject3224
Withdrew: Death611

Outcome measures

PrimaryChange in Self Reported Physical Recovery

As determined using the Physical Component Score of Short form (SF) SF-36. Score range: 0-100, higher scores indicate a better health state. The change is between baseline and 12 months.

Time frame:
12 months
Reported as:
Mean · score on a scale
Change in Self Reported Physical Recovery
score on a scaleTMH InterventionUsual Care
Change in Self Reported Physical Recovery40.42 ± 12.8239.18 ± 12.43
PrimaryChange in Physical Recovery

As determined using the Short Physical Performance Battery (SPPB). SPPB total score ranges from 0 (worst performance) to 12 points (best performance). The change was determined between baseline and 12 months.

Time frame:
12 months
Reported as:
Mean · score on a scale
Change in Physical Recovery
score on a scaleTMH InterventionUsual Care
Change in Physical Recovery8.28 ± 3.888.00 ± 3.60
PrimaryChange in Self Reported Psychological Recovery

As determined using the Mental Component Score of SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 12 months.

Time frame:
12 months
Reported as:
Mean · score on a scale
Change in Self Reported Psychological Recovery
score on a scaleTMH InterventionUsual Care
Change in Self Reported Psychological Recovery53.92 ± 10.0253.21 ± 10.82
PrimaryHealthcare Utilization

As determined by hospital readmission

Time frame:
12 months
Reported as:
Count of participants · Participants
Healthcare Utilization
ParticipantsTMH InterventionUsual Care
Readmission within 1 year7071
No readmission146142
PrimaryChange in Self Reported Physical Recovery

As determined using the Physical Component Score of Short form (SF) SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 6 months.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change in Self Reported Physical Recovery
score on a scaleTMH InterventionUsual Care
Change in Self Reported Physical Recovery36.86 ± 12.5338.04 ± 12.09
PrimaryChange in Physical Recovery

As determined using the Short Physical Performance Battery (SPPB). SPPB total score ranges from 0 (worst performance) to 12 points (best performance). The change was determined between baseline and 6 months.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change in Physical Recovery
score on a scaleTMH InterventionUsual Care
Change in Physical Recovery7.02 ± 4.397.66 ± 3.91
PrimaryChange in Self Reported Psychological Recovery

As determined using the Mental Component Score of SF-36. Score range: 0-100, higher scores indicate a better health state. The change was determined between baseline and 6 months.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change in Self Reported Psychological Recovery
score on a scaleTMH InterventionUsual Care
Change in Self Reported Psychological Recovery53.72 ± 10.2253.01 ± 10.64
SecondaryChange in Depression Symptoms

As determined using the (Patient Health Questionnaire) PHQ-9. The scale is from 1 - 27 with higher scores related to worse depression severity. The change was determined between baseline and 12 months.

Time frame:
12 months
Reported as:
Median · score on a scale
Change in Depression Symptoms
score on a scaleTMH InterventionUsual Care
Change in Depression Symptoms4.31 ± 4.794.44 ± 5.58
SecondaryChange in Anxiety Symptoms

As determined using the (Generalized Anxiety Disorder) GAD-7. Scores range from 0-21, with higher scores indicating worse symptoms. The change was determined between baseline and 12 months.

Time frame:
12 months
Reported as:
Mean · score on a scale
Change in Anxiety Symptoms
score on a scaleTMH InterventionUsual Care
Change in Anxiety Symptoms3.39 ± 4.363.61 ± 4.80
SecondaryCost Effectiveness

As determined using the cost-effectiveness ratio

Time frame:
6 and 12 months

No measurements were reported for this outcome.

SecondaryChange in Depression Symptoms

As determined using the (Patient Health Questionnaire) PHQ-9. The scale is from 1 - 27 with higher scores related to worse depression severity. The change was determined between baseline and 6 months.

Time frame:
6 months
Reported as:
Median · score on a scale
Change in Depression Symptoms
score on a scaleTMH InterventionUsual Care
Change in Depression Symptoms4.73 ± 54.31 ± 4.62
SecondaryChange in Anxiety Symptoms

As determined using the (Generalized Anxiety Disorder) GAD-7. Scores range from 0-21, with higher scores indicating worse symptoms. The change was determined between baseline and 6 months.

Time frame:
6 months
Reported as:
Mean · score on a scale
Change in Anxiety Symptoms
score on a scaleTMH InterventionUsual Care
Change in Anxiety Symptoms3.64 ± 4.363.60 ± 4.31

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TMH Intervention6/216 (2.8%)0/216 (0%)0/216 (0%)
Usual Care11/213 (5.2%)0/213 (0%)0/213 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)TMH InterventionUsual CareTotal
Mean69.6 ± 10.968.9 ± 10.669.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)TMH InterventionUsual CareTotal
Female114114228
Male10299201
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TMH InterventionUsual CareTotal
Race — Black191837
Race — Other224
Race — White195193388
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TMH InterventionUsual CareTotal
Ethnicity — Hispanic213
Ethnicity — Non-Hispanic214212426
Region of Enrollment
Region of Enrollment(participants)TMH InterventionUsual CareTotal
United States216213429
Mechanism of Injury
Mechanism of Injury(Participants)TMH InterventionUsual CareTotal
Fall121122243
Motor Vehicle Crash6666132
Other292554
Injury Severity Score
Injury Severity Score(score)TMH InterventionUsual CareTotal
Mean12 ± 3.912.5 ± 5.112.3 ± 4.6
Hospital Length of Stay
Hospital Length of Stay(days)TMH InterventionUsual CareTotal
Median7 (4 to 10)6 (4 to 10)7 (4 to 10)
08

Study locations

4 sites
  • Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
  • IU Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • St. Vincent Indianapolis
    Indianapolis, Indiana 46260, United States
  • UW Health - University Hospital
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Ortiz D, Meagher AD, Lindroth H, Holler E, Gao S, Khan B, Lasiter S, Boustani M, Zarzaur B. A trauma medical home, evaluating collaborative care for the older injured patient: study protocol for a randomized controlled trial. Trials. 2020 Jul 16;21(1):655. doi: 10.1186/s13063-020-04582-x. PubMed 32678026 ↗

Study documents

  • Protocol and statistical analysis plan · Jul 27, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03108820
Lead sponsor
Indiana University
Collaborators
National Institutes of Health (NIH), Northwestern University, University of Missouri, Kansas City, National Institute on Aging (NIA)
Responsible party
Ben Zarzaur, MD, MPH (Associate Professor of Surgery, Indiana University) — Principal investigator
First posted
Apr 11, 2017
Start date
Oct 1, 2017
Primary completion
Mar 1, 2023
Completion
Mar 1, 2023
Results posted
Jun 24, 2024
Last update
Jun 24, 2024

Study contacts

Ben Zarzaur, MD, MPH
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion